<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT944-366</title>
	</head>
	<body>
		<main>
			<p>941229 FT  29 DEC 94 / UK Company News: Wellcome set to make inroads into US market Wellcome, the drugs group, yesterday predicted it would win a larger share of the US market - the world's largest - following approval of two products by the Food and Drug Administration. The company welcomed the decision to approve Lamictal, its anti-epilepsy treatment, and Navelbine, which it claimed would be the first new cancer drug in the US for 20 years. Both products will be marketed by Burroughs Wellcome, its US arm. The potential market for Navelbine is estimated at Dollars 100m (Pounds 64m) a year. Lamictal is expected to win a sizeable share of sales in North America. The world market for such drugs is put at Pounds 1bn.</p>
		</main>
</body></html>
            